Eli Lilly is aware of this fact, which helps explain why it acquired Adverum Biotechnologies in late 2025 and just agreed to ...

Eli Lilly stock prepares €15B Abivax acquisition as tirzepatide revenue hits $24.8B. Orforglipron oral weight loss drug ...

Momentum in weight-loss drugs is the main reason why Eli Lilly's stock soared in 2025. Over the last five years it is up 459%, and that is excluding dividends. It is the largest drugmaker in the world ...

I initiate my coverage on Eli Lilly with a 'Buy' after an eventful Q2 earnings season. The stock looks attractively valued, with P/E ratios well below historical averages and robust momentum in ...

Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the company's lead in this niche of the industry. Even after their strong run, Lilly's ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Hilary Brueck Every time Hilary publishes a story, you’ll get an alert straight to your inbox!